Euronext

Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

Retrieved on: 
Tuesday, January 2, 2024
Acquisition, Executive Committee, Galapagos NV, Euronext, Letter, Investment, Patient, Management

The agreement follows the signing of a letter of intent as announced on 30 October 2023.

Key Points: 
  • The agreement follows the signing of a letter of intent as announced on 30 October 2023.
  • “We would like to thank Michele for his contributions to Galapagos and are confident that his planned transition to Alfasigma will ensure business continuity through his close collaboration with the Jyseleca® team.
  • As previously announced, under the terms of the agreement, Alfasigma will acquire the entire Jyseleca® business, including the European and UK Marketing Authorizations, the commercial, medical affairs and development activities for Jyseleca® and approximately 400 Galapagos positions in 14 European countries.
  • Galapagos will contribute up to €40 million to Alfasigma by June 2025 for Jyseleca® related development activities.

argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 2, 2024
Euronext, Conference, Webcast

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:00 a.m. PT.

Key Points: 
  • Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:00 a.m. PT.
  • A live webcast of the presentation may be accessed on the Investor section of the argenx website at argenx.com/ investors .
  • A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Retrieved on: 
Friday, December 22, 2023
HEC Paris, Hoechst AG, AstraZeneca, Business, Research, Merck & Co., Vaccine, MBA, Chemical engineering, Therapy, Euronext, GSK, University, Moses Austin, Merck, Patient, Alexion, Pharmaceutical industry

At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected, consistent with the recommendations of the board of directors.

Key Points: 
  • At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected, consistent with the recommendations of the board of directors.
  • The Company’s shareholders also approved the appointments of Mr. Marc Dunoyer and Dr. Tyrell Rivers as directors of the Cellectis board of directors, which appointment remains subject to the completion of the Additional Investment.
  • “We are grateful to our shareholders for supporting the Additional Investment and we are looking forward to welcoming Mr. Dunoyer and Dr. Rivers to our board of directors.
  • The detailed results of the vote and the resolutions are available on Cellectis’ website:

argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

Retrieved on: 
Wednesday, December 20, 2023
Biology, Patient, Efgartigimod alfa, Autoantibody, PV, Consistency, Literature, Pemphigus vulgaris, Conference call, Euronext, PD, Steroid, Pemphigus foliaceus, Growth, Safety, Immunoglobulin G

argenx will not pursue additional development in pemphigus and plans to prioritize clinical development of efgartigimod in its ongoing severe autoimmune indications.

Key Points: 
  • argenx will not pursue additional development in pemphigus and plans to prioritize clinical development of efgartigimod in its ongoing severe autoimmune indications.
  • “We are disappointed by today’s results, particularly for pemphigus patients who have seen little innovation in this treatment space,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx.
  • “We are grateful to the pemphigus community and all involved in the ADDRESS study, including patients, healthcare professionals, and our argenx teams,” continued Dr. Truyen.
  • Consistent pharmacodynamic (PD) effect of efgartigimod SC: Treatment with efgartigimod SC led to total immunoglobulin G (IgG) and desmoglein autoantibody (DSG-1 and DSG-3) reductions up to 75%.

Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301

Retrieved on: 
Tuesday, December 19, 2023
Prognosis, Galapagos NV, Euronext, Patient, B-cell maturation antigen, Multiple myeloma, Safety, Quality of life, BCMA

This is Galapagos’ third oncology CAR-T program in clinical development.

Key Points: 
  • This is Galapagos’ third oncology CAR-T program in clinical development.
  • GLPG5301 is an autologous, second-generation/4-1BB B-cell maturation antigen (BCMA)-directed CAR-T product candidate, administered as an intravenous infusion of a fresh product in a single fixed dose, at point-of-care.
  • “Patients living with relapsed/refractory multiple myeloma have a very poor prognosis and a significant high unmet medical need for novel treatment options.
  • “We are very pleased that the first patient with rrMM in PAPILIO-1 has been dosed with our BCMA CAR-T candidate, GLPG5301.

Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®

Retrieved on: 
Monday, December 11, 2023
Mont-Saint-Guibert, Conference, Obstructive sleep apnea, FDA, Epworth Sleepiness Scale, ESS, Euronext, Patient, AHI, CCC, Medical device

The investigator-sponsored case series was presented by Dr. Christian Plettenberg from the Universitätsklinikum Düsseldorf on December 8, 2023.

Key Points: 
  • The investigator-sponsored case series was presented by Dr. Christian Plettenberg from the Universitätsklinikum Düsseldorf on December 8, 2023.
  • Results showed an average apnea-hypopnea index (AHI) decrease of 73% and Epworth Sleepiness Scale (ESS) decrease of 58%.
  • “These data further validate Genio’s bilateral stimulation approach in treating CCC patients, who represent approximately 30% of HGNS eligible-to-treat OSA patients and are contraindicated to commercially available HGNS therapy in the US.
  • “I want to thank Dr. Plettenberg and his colleagues for their important work which reinforces Genio as a treatment solution for both non-CCC and CCC patients.”

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

Retrieved on: 
Saturday, December 9, 2023
Cytokine release syndrome, DL2, Symantec Endpoint Protection, CRR, Mantle cell lymphoma, Doctor of Philosophy, University of Barcelona, Society, Galapagos NV, Euronext, Cancer, ASH, University, Non-Hodgkin lymphoma, Indolent lymphoma, RT, Richter's transformation, Poster, Congress, CRS, Patient, CD19, Safety, KOL, Pharmaceutical industry

The data suggest that Galapagos’ CAR-T point-of-care manufacturing platform can deliver fresh product in a median vein-to-vein time of seven days.

Key Points: 
  • The data suggest that Galapagos’ CAR-T point-of-care manufacturing platform can deliver fresh product in a median vein-to-vein time of seven days.
  • To further build a robust data package, patient recruitment of the Phase 1 dose-finding part of ATALANTA-1 is ongoing.
  • The data suggest that Galapagos’ point-of-care platform can deliver fresh product in a median vein-to-vein time of seven days.
  • Seven-day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL including Richter’s Transformation: Results from the Phase 1 Euplagia-1 Trial

Publication Relating to a Transparency Notification

Retrieved on: 
Friday, December 8, 2023
Disclosure, Euronext, Person, Mont-Saint-Guibert, Nightclub

Mont-Saint-Guibert (Belgium), December 8, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

Key Points: 
  • Mont-Saint-Guibert (Belgium), December 8, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.
  • On December 6, 2023, Nyxoah received a transparency notification from Deerfield Partners, L.P. indicating that Deerfield Partners, L.P. crossed the 3% threshold on November 30, 2023, after which Deerfield Partners, L.P. holds 856,085 shares, representing 2.99% of the total number of voting rights on November 30, 2023 (28,673,985).
  • The notification dated December 6, 2023 contains the following information:
    Persons subject to the notification requirement:
    Deerfield Partners, L.P. (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
    Deerfield Mgmt, L.P. (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
    J.E.
  • Flynn Capital, LLC (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
    Deerfield Management Company, L.P. (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
    Flynn Management LLC (with address at 345 Park Ave S., 12th FL, New York, NY 10010 United States)
    Date on which the threshold was crossed: November 30, 2023

Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023

Retrieved on: 
Thursday, December 7, 2023
Associate, MMSc, Survival, Lymphoid leukemia, University of Antwerp, MD, Doctor of Philosophy, Galapagos NV, Euronext, Galápagos Islands, University, CLL, Oncology, PST, Patient, University of Chicago, Harvard Medical School, Clinical research, KOL, FACP, Management

Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST.

Key Points: 
  • Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST.
  • The in-person event will be held at the San Diego Marriott Gaslamp Quarter in the Presidio Ballroom B/C.
  • To register as an in-person attendee, please click here .
  • Galapagos leadership, including Paul Stoffels1, MD, CEO and Chairman, will provide updates on:
    A live question and answer will follow the formal presentations.

Akobo Minerals to Present at the Clean Energy and Precious Metals Virtual Investor Conference December 6th

Retrieved on: 
Monday, December 4, 2023
Euronext, Håkon Evjen, Conference

OSLO, Sweden, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Akobo Minerals (Euronext and Frankfurt: AKOBO) (OTCQX: AKOBF).

Key Points: 
  • OSLO, Sweden, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Akobo Minerals (Euronext and Frankfurt: AKOBO) (OTCQX: AKOBF).
  • The Scandinavian-based Ethiopian gold exploration and boutique mining company today announced that Jørgen Evjen, CEO, will present live at the Clean Energy and Precious Metals Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on December 6th.
  • This will be a live, interactive online event where investors are invited to ask the company questions in real-time.
  • It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.